http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
악성 림프종 환자에서 BEAM 고용량화학요법과 자가조혈모세포이식
박진노(Jin No Park),홍영선(Young Seon Hong),송치원(Chee Won Song),조석구(Seok Goo Cho),이종욱(Jong Wook Lee),민우성(Woo Sung Min),김춘추(Chun Choo Kim),이경식(Kyung Shick Lee) 대한내과학회 2001 대한내과학회지 Vol.61 No.3
N/A Background : The long-term survival in patients with non-Hodgkin's lymphoma (NHL) after conventional chemotherapy is about 35% and the rest of the patients tend to have relapse. So, in relapsed or refractory NHL, the outcome of patients undergoing high-dose chemotherapy and autologous peripheral stem cell transplantation (APBSCT) was evaluated, and the main prognostic factors were determined. Methods : 17 patients with relapsed or resistant NHL (5 complete response group, 7 partial response group, 4 primary refractory group, 1 resistant relapse) underwent BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy and APBSCT between July 1997 and February 1999. Results : The median follow-up duration was 17 months (range: 4-47). The response rate was 58.3% (complete response 33.3%, partial response 25.0%) in 12 patients in whom complete response group was not included. The 2-year, 3-year overall response rate were 41.2%, 27.5%, respectively. And 2-year progression free survival was 35.3%. The disease status before high-dose chemotherapy was the only significant prognostic factor in determining overall survival (univariate p=.024, multivariate p=.059) and progression free survival (univariate p=.013, multivariate p=.026). Patients with complete response to salvage regimen had better overall survival (p=.021) and progression free survival (p=.008) than patients with refractory response. WBC (≥ 1,000/uL) was recovered at the median 11 days (range; 8-24), and platelet (≥ 50,000/uL) was recovered at the median 18 days (range; 9-44). There was no treatment-related death and no grade 3 and 4 toxicity. Neutropenic infection was in 4 patients (1 Herpes zoster, 1 typhlitis, 1 perianal infection, 1 otitis externa). Conclusion : The pre-transplant disease status was the main prognostic factor. Patients with complete response to salvage regimen had the significant benefit in survival from high-dose chemotherapy and APBSCT, but patients with refractory or resistant relapsed NHL did not have any significant benefit.(Korean J Med 61:255-263, 2001)
윤형도,이한영,구자현,장진현,박종훈,이경식,Yoon, Hyung-Do,Lee, Han-Young,Ku, Ja-Hyon,Chang, Jin-Hyeon,Park, Jong-Hoon,Lee, Kyung-Shik 대한전자공학회 1999 電子工學會論文誌, D Vol.d36 No.11
온도보상용 광섬유격자필터를 실현하기 위하여 서로다른 열팽창계수를 갖는 두물질을 이용하여 패키징을 한 후 -10도부터 70도 사이에서 온도변화실험을 하였다. 그결과 003nm이하의 파장변화율을 보여 상기온도 범위내에서 일반의 온도보상되지 않는 광섬유 격자에 비하여 약 30배의 온도보상 효과를 보였다. To temperature-compensate the Bragg wavelength of fiber grating filters two materials with different thermal expansion coefficients were depolyed for packaging. After temperature-compensation packaging the maximum difference of the Bragg wavelength in the temperature range of $-10^{\circ}C$ to $70^{\circ}C$ was 0.03nm, which is only about one thirtiety of the Bragg wavelength shift of the temperature-uncompensated fiber grating filter.
김동섭 ( Kim Dong-sup ),이종진 ( Lee Kyung-sik ),이경식 ( Lee Jong-jin ),황종서 ( Hwang Jong-seo ),황길순 ( Hwang Gilson ) 한국농공학회 2003 한국농공학회 학술대회초록집 Vol.2003 No.-
This study was studied in Tamjin liver that is situated jangheung-gun Jeollanm-do. Fishways that was studied with the emphasis on Ice harbour type fishway analyzed efficiencies. In result, Ice harbor type fishway discovered 12species of fish among 13species in Tamjin liver. But, most other fishways have discovered a few fishes. Because most fishways established ill station and managed badly.
재발 및 불응성 비호즈킨 림프종 환자의 치료에서 IVAM ( Ifosfamide , VP-16 , Ara-C , Methotrexate ) 복합화학요법의 치료 효과
송치원(Chi Won Song),박진노(Jin No Park),조석구(Seok Goo Cho),이종욱(Jong Wook Lee),홍영선(Young Seon Hong),민우성(Woo Sung Min),김춘추(Chun Choo Kim),이경식(Kyung Shick Lee) 대한내과학회 2001 대한내과학회지 Vol.61 No.2
N/A Background : Patients with non-Hodgkin's lymphoma who do not respond to first-line chemotherapy or those who relapse after obtaining a complete response have a poor prognosis and are rarely cured with usual salvage chemotherapy. We investigated the treatment responses, toxicities, prognostic factors and mobilization efficacy of peripheral blood stem cells (PBSC) used as salvage chemotherapy. Methods : 55 patients with refractory (36) or relapsed (19) NHL were treated from Novembr 1997 to October 1999 with IVAM (ifosfamide, etoposide, cytarabine, methotrexate) regimen. Each patients was scheduled to receive one to three cycles of chemotherapy. When the leukocyte count reached 5×109/L after chemotherapy, PBSC collection was performed. The treatment was repeated every 4 weeks. Results : The median age was 48 years (range, 19-76). Median 2.1 cycles of chemotherapy were administered. 15 patients (27.3%) achieved complete response and 29 (52.7%) partial response, with an overall response rate of 80.0%. Myelosuppression was the major toxicity, with 98.2% of grade 3, 4 neutropenia and thrombocytopenia, but there was no serious hemorragic event. Neutropenic fever occurred in 25.5% of the patients with one treatment-related death due to sepsis. Non-hematologic toxicity was modest. PBSC was collected in 36 patients for high dose chemotherapy and autologous stem cell transplantation. The median number of mononuclear cells collected was 9.9×108/kg and the median number of CD34(+) cells collected was 11.9×106/kg. After a median follow-up of 13 months (range, 3-26), median progression free survival were 12 months and median overall survival has not been reached yet. 1-year overall survival and progression free survival were 61.9% and 46.1%, respectively. In univariate analyses, unfavorable prognosis was associated with poor performance status (p=0.001), high LDH (p=0.041), stage III,IV (p=0.04), extralymphatic lesion (p=0.027), B sx (p=0.034), bone marrow involvement (p=0.039) and performing high dose chemotherapy (p=0.005). Multivariate analysis showed that performance status(p=0.0042), B sx(p=0.049) was a significant independent risk factors for death. Conclusion : These results suggest that IVAM is an effective salvage chemotherapy for refractory or relapsed NHL and allow effective PBSC collection for high dose chemotherapy and autologous PBSCT.(Korean J Med 61:141-150, 2001)
이경식,김춘추,홍영선,김훈교,김동집,진종률 대한내과학회 1986 대한내과학회지 Vol.30 No.1
A retrospective study was performed for 3g patients with acute myelogenous leukemia, who were treated with classical TAD regimen(23 patients) or augmented TAD 3~10 regimen(16 patients) as a remission induction chemotherapy. Complete remission(CR, of which definition is excluding $quot; relapse within 3 months after application of chemotherapy $quot; ) rate, duration of remission, were compared between each group. The CR rate in augmented TAD 3~10 group was 81.3%, and was superior to that in classical TAD group (56.5%). Overall CR rate was 66.7%. The median duration of remission in all was 10.5 months(3~44), in classical TAD group, 13.1 months(5~44), and in augmented TAD 3~10 group, 7.8months (3~19). The duration of remission would be prolonged, if we perform long term follow up study in augmented TAD 3~10 group. In patients with consolidation chemotherapy after CR, the median duration of remission(13.5 months, range 344 months) was longer than that(7.6 months, range 311 months) in patients without consolidation chemotherapy. Our data suggests that: (1) augmented TAD 3~10 regimen, which was modified from conventional TAD regimen by adding cytosine arabinoside of which function is killing the recruit S phase blasts on day 8 and 10, for 3 days, was superior to classical TAD regimen for induction chemotherapy of acute myelogenous leukemia, (2) consolidation chemotherapy after CR would prolong the duration of remission in patients with acute myelogenous leukemia.
신경손상이 있던 환자에서의 Cisplatin 에 의한 말초신경병
이경식,윤선애,문한림,홍영선,김훈교,김동집,진종률,윤광무 대한내과학회 1991 대한내과학회지 Vol.41 No.5
One of the major toxic effects of cisplatin is sensory peripheral neuropathy which is dose-related, but the risk factor is unknown. We experienced cisplatin-induced peripheral neuropathy confined to rhe extermities of previous abnormal neurologic manifestations in 3 patients who had a history of neuropathy. The first case with tonsillar cancer had a recent history of paraplegia by L1 cord compression and recovered completely with radiotherapy. After he received cisplatin 280mg/m², he developed grade I peripheral neuropathy on both lower extremities. Additional cisplatin treatment induced grade III peripheral neuropathy. The second case had a history of right hemiparesis by cerebral infarction 10 years ago. Stage IV laryngeal cancer was diagnosed, and he received cisplatin 80 mg/m². He developed grade I peripheral neuropathy on the right extremities 1,'day after chemotherapy. The third case had a history of paraparesis by tuberculous meningitis 10 years ago. Stage III laryngeal cancer was diagnosed. He developed grade II peripheral neuropathy on both lower extremities 1 day after cisplatin 100 mg/m² treatment, and after a second cycle of chemotherapy grade III peripheral neuropathy developed. The first and second cases recovered completely after discontinuation of cisplation treatment. We can conclude that previous neurologic damage could be a hight-risk factor in the development of cisplatin-induced peripheral neuropathy.